Sign up Australia
Proactive Investors - Run By Investors For Investors

Holista CollTech to gain European bakery expert as shareholder

Holista CollTech to gain European bakery expert as shareholder

Holista Colltech (ASX:HCT) will issue shares up to a 10% stake to the major shareholder of Swiss Panadoro Group and Matzingen-based Veripan AG, Europe’s largest independent supplier of specialty baking ingredients.

Holista, which recently announced a scientific breakthrough to make white bread healthier with its combination of a blend of okra, lentils, barley and fenugreek with Veripan’s sourdough formula to form PANATURA® GI, will sell shares and free attaching options to Meiert Grootes in tranches.

Grootes will acquire the shares at $0.115 amounting to A$454,734, via a direct placement, equal to a 2.5% holding.

Free attached options will be issued for 11,862,616 new shares, which will enlarge his stake in Holista by a further 7.5% exercisable at various strike prices.

Holista's patented formula scored a Glycemic Index (“GI”) reading of 53, the lowest-ever achieved by any clean-label white bread in a clinical trial.

It will begin marketing PANATURA® GI to the US$170 billion white bread market, a rollout in which Grootes will play a significant role given his 27 years’ experience in the bread industry and contacts in the milling and bakery industry.

Clearly, interesting times are ahead in the roll-out of the product.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Register here to be notified of future HCT Company articles
View full HCT profile

Holista Colltech Ltd Timeline

Related Articles

Benjamin Franklin wearing a medical mask
March 25 2016
Constellation has identified a significant market opportunity in healthcare billing management.
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
January 30 2016
A return to Nasdaq and ongoing commercial success promises to address a significant disconnect in the valuation of Pressure Bioscience...

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.